• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于腺相关病毒9型(AAV9)的基因治疗设计改进,用于治疗与相关 Leigh 综合征,毒性最小。

Improved AAV9-based gene therapy design for -related Leigh syndrome with minimal toxicity.

作者信息

Ling Qinglan, Rioux Matthew, Higgs Harrison, Hu Yuhui, Dwyer Scarlett E, Gray Steven J

机构信息

Department of Genetic & Cellular Medicine, Horae Gene Therapy Center, UMass Chan Medical School, Worcester, MA 01605, USA.

Department of Microbiology, UMass Chan Medical School, Worcester, MA 01605, USA.

出版信息

Mol Ther Methods Clin Dev. 2025 Aug 11;33(3):101554. doi: 10.1016/j.omtm.2025.101554. eCollection 2025 Sep 11.

DOI:10.1016/j.omtm.2025.101554
PMID:40893166
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12398787/
Abstract

Surfeit locus protein 1 (SURF1)-related Leigh syndrome is an early-onset neurodegenerative disorder characterized by a reduction in complex IV activity that disrupts mitochondrial function. Currently, there are no disease-modifying treatments available. Previously, we reported that a gene replacement therapy for -related Leigh syndrome was developed, which showed improved complex IV activity and restored exercise-induced lactate acidosis, as well as a high safety profile in wild-type (WT) mice. However, further investigations of this original SURF1 vector design uncovered cytotoxicity in multiple tissues of WT rats despite having minimal immune responses. We hypothesized that this cytotoxicity was elicited by SURF1 protein overexpression driven by a strong ubiquitous promoter, CBh. Here, we report the development of an improved gene therapy for SURF1 Leigh syndrome by utilizing a different promoter and polyadenylation sequence. Our data showed that, with lower SURF1 protein expression, the new design conferred a similar level of efficacy, but with minimal cytotoxicity in mice or rats. We propose this new vector design as a promising therapeutic candidate for -related Leigh syndrome, warranting further translational studies.

摘要

与过表达位点蛋白1(SURF1)相关的 Leigh 综合征是一种早发性神经退行性疾病,其特征是复合体IV活性降低,从而破坏线粒体功能。目前,尚无改善病情的治疗方法。此前,我们报道已开发出一种针对相关 Leigh 综合征的基因替代疗法,该疗法在野生型(WT)小鼠中显示出复合体IV活性提高、运动诱发的乳酸性酸中毒得到恢复,且安全性良好。然而,对这种原始SURF1载体设计的进一步研究发现,尽管免疫反应极小,但在WT大鼠的多个组织中仍存在细胞毒性。我们推测这种细胞毒性是由强泛在启动子CBh驱动的SURF1蛋白过表达引起的。在此,我们报告通过使用不同的启动子和聚腺苷酸化序列,开发出一种针对SURF1 Leigh综合征的改进基因疗法。我们的数据表明,在SURF1蛋白表达较低的情况下,新设计具有相似的疗效水平,但在小鼠或大鼠中细胞毒性极小。我们提出这种新的载体设计作为相关Leigh综合征有前景的治疗候选方案,值得进一步开展转化研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/3f27805df1b4/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/154039771c17/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/5e134037fef2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/a46f3588753e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/7aca58c43443/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/041cbccb4fe4/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/98f975b38435/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/3f27805df1b4/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/154039771c17/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/5e134037fef2/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/a46f3588753e/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/7aca58c43443/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/041cbccb4fe4/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/98f975b38435/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f81/12398787/3f27805df1b4/gr6.jpg

相似文献

1
Improved AAV9-based gene therapy design for -related Leigh syndrome with minimal toxicity.基于腺相关病毒9型(AAV9)的基因治疗设计改进,用于治疗与相关 Leigh 综合征,毒性最小。
Mol Ther Methods Clin Dev. 2025 Aug 11;33(3):101554. doi: 10.1016/j.omtm.2025.101554. eCollection 2025 Sep 11.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Adeno-associated viral vector serotype 9-based gene replacement therapy for -related Leigh syndrome.基于9型腺相关病毒载体的基因替代疗法治疗与[具体疾病]相关的Leigh综合征。 (你提供的原文中“-related”前缺失了疾病相关信息)
Mol Ther Methods Clin Dev. 2021 Sep 7;23:158-168. doi: 10.1016/j.omtm.2021.09.001. eCollection 2021 Dec 10.
4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Mitochondrial DNA-Associated Leigh Syndrome Spectrum线粒体DNA相关的 Leigh 综合征谱系
6
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
7
Treatment for mitochondrial disorders.线粒体疾病的治疗。
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD004426. doi: 10.1002/14651858.CD004426.pub3.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
Psychological therapies for post-traumatic stress disorder and comorbid substance use disorder.创伤后应激障碍及共病物质使用障碍的心理治疗
Cochrane Database Syst Rev. 2016 Apr 4;4(4):CD010204. doi: 10.1002/14651858.CD010204.pub2.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.

本文引用的文献

1
SURF1 Deficiency: Expanding on Disease Phenotype and Assessing Disease Burden by Describing Clinical and Biochemical Phenotype.SURF1缺乏症:通过描述临床和生化表型扩展疾病表型并评估疾病负担
Am J Med Genet A. 2025 Apr;197(4):e63947. doi: 10.1002/ajmg.a.63947. Epub 2024 Dec 5.
2
Expression and distribution of rAAV9 intrathecally administered in juvenile to adolescent mice.rAAV9经鞘内注射在幼年至青春期小鼠体内的表达与分布。
Gene Ther. 2024 Nov 5. doi: 10.1038/s41434-024-00498-2.
3
Restoration of defective oxidative phosphorylation to a subset of neurons prevents mitochondrial encephalopathy.
修复部分神经元的缺陷氧化磷酸化可预防线粒体脑病。
EMBO Mol Med. 2024 Sep;16(9):2210-2232. doi: 10.1038/s44321-024-00111-4. Epub 2024 Aug 21.
4
The power and potential of mitochondria transfer.线粒体转移的力量和潜力。
Nature. 2023 Nov;623(7986):283-291. doi: 10.1038/s41586-023-06537-z. Epub 2023 Nov 8.
5
AAV-based in vivo gene therapy for neurological disorders.基于腺相关病毒的神经疾病体内基因治疗。
Nat Rev Drug Discov. 2023 Oct;22(10):789-806. doi: 10.1038/s41573-023-00766-7. Epub 2023 Sep 1.
6
Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies.鞘内注射 AAV9/AP4M1 基因治疗遗传性痉挛性截瘫 50 型在临床前研究中显示出安全性和疗效。
J Clin Invest. 2023 May 15;133(10):e164575. doi: 10.1172/JCI164575.
7
Biodistribution of Adeno-Associated Virus Gene Therapy Following Cerebrospinal Fluid-Directed Administration.经脑脊液给药的腺相关病毒基因治疗的生物分布。
Hum Gene Ther. 2023 Feb;34(3-4):94-111. doi: 10.1089/hum.2022.163.
8
overexpression of frataxin causes toxicity mediated by iron-sulfur cluster deficiency.弗里德赖希共济失调蛋白的过表达会导致由铁硫簇缺乏介导的毒性。
Mol Ther Methods Clin Dev. 2022 Feb 7;24:367-378. doi: 10.1016/j.omtm.2022.02.002. eCollection 2022 Mar 10.
9
Characterization of AAV-mediated dorsal root ganglionopathy.腺相关病毒介导的背根神经节病变的特征描述。
Mol Ther Methods Clin Dev. 2022 Feb 1;24:342-354. doi: 10.1016/j.omtm.2022.01.013. eCollection 2022 Mar 10.
10
AAV9/MFSD8 gene therapy is effective in preclinical models of neuronal ceroid lipofuscinosis type 7 disease.腺相关病毒 9/ 溶质载体家族 25 成员 8 基因治疗在神经元蜡样脂褐质沉积症 7 型疾病的临床前模型中是有效的。
J Clin Invest. 2022 Mar 1;132(5). doi: 10.1172/JCI146286.